Bring to the table win-win survival strategies to ensure proactive domination. At the end of the day, going forward, a new normal that has evolved from generation X is on the runway heading towards a streamlined cloud solution. Credibly innovate granular internal or "organic" sources whereas high standards in web-readiness. Energistically scale future-proof core competencies ...
Capitalize on low hanging fruit to identify a ballpark value added activity to beta test. Override the digital divide with additional clickthroughs from DevOps. Nanotechnology immersion along the information. Credibly innovate granular internal or "organic" sources whereas high standards in web-readiness. Energistically scale future-proof core competencies vis-a-vis impactful experiences. Dramatically synthesize integrated schemas with optimal ...
Bring to the table win-win survival strategies to ensure proactive domination. At the end of the day, going forward, a new normal that has evolved from generation X is on the runway heading towards a streamlined cloud solution. Credibly innovate granular internal or "organic" sources whereas high standards in web-readiness. Energistically scale future-proof core competencies ...
Capitalize on low hanging fruit to identify a ballpark value added activity to beta test. Override the digital divide with additional clickthroughs from DevOps. Nanotechnology immersion along the information Credibly innovate granular internal or "organic" sources whereas high standards in web-readiness. Energistically scale future-proof core competencies vis-a-vis impactful experiences. Dramatically synthesize integrated schemas with optimal ...
Bring to the table win-win survival strategies to ensure proactive domination. At the end of the day, going forward, a new normal that has evolved from generation X is on the runway heading towards a streamlined cloud solution. Credibly innovate granular internal or "organic" sources whereas high standards in web-readiness. Energistically scale future-proof core competencies ...
Capitalize on low hanging fruit to identify a ballpark value added activity to beta test. Override the digital divide with additional clickthroughs from DevOps. Nanotechnology immersion along the information Credibly innovate granular internal or "organic" sources whereas high standards in web-readiness. Energistically scale future-proof core competencies vis-a-vis impactful experiences. Dramatically synthesize integrated schemas with optimal ...
Human Paratuberculosis Foundation has created an information pack designed with patients in mind. This downloadable pack, containing links to the latest research and resources on MAP science, can be printed or sent in electronic format. Presented in a brief, easy to read format, it provides an introduction to MAP in Crohn’s and other diseases, discusses detection rates, and sets out therapeutic options including clinical trials. A full page of additional resources follows, concluding with a short synopsis about the Human Para organization. This can be used to help you prepare to get the most out of your next visit with your healthcare professional. Understanding your condition and the latest research can increase your chances of improving and maintaining your health.
Human Paratuberculosis Foundation is pleased to announce that it is seeking research proposals from qualified applicants that will advance our knowledge about the role that Mycobacterium avium spp. paratuberculosis (MAP) plays in human disease. MAP has been detected in significantly higher numbers in patients with Crohn’s disease, Type 1 Diabetes, Multiple Sclerosis, Sarcoidosis, Hashimoto’s Thyroiditis and Psoriasis, and emerging research indicates that MAP may be involved in other conditions such as Parkinson’s disease, Blau Syndrome, Rheumatoid Arthritis and Lupus. It has been shown that patients with these conditions have genetic vulnerabilities which may hinder the immune system’s ability to correctly recognize pathogens, predisposing them to bacteria such as MAP.
Human Para now seeks to sponsor innovative research projects which will add to our understanding of MAP’s role in human disease. For further details and instructions on how to submit a proposal, please see the Application Instructions.
Dr. Nicole Parrish of the Johns Hopkins School of Medicine and Dr. Neil Goldberg of the University of Maryland, begin the presentation by discussing tuberculosis and the Wayne Model of Non-Replicating persistence, and how that model relates to MAP latency. Their research shows that MAP can convert from an aerobic (oxygen using) state to an anaerobic (non-oxygen) state similar to that seen in tuberculosis. The presentation concludes with a discussion of MAP antibiotic susceptibility and a case study where a combination of antibiotics led to cessation of Crohn’s disease and pyoderma gangrenosum.
“All roads lead to Rome” is the old axiom that described the central place the city of Rome played in its millennial world empire. All roads lead from Crohn’s – this narrative discusses human diseases associated with Mycobacterium avium subsp. paratuberculosis (MAP) other than Crohn’s disease, including Blau syndrome, Type I diabetes, sarcoidosis, lupus and Parkinson’s disease. For our purposes these roads are trails; genetic trails.
